Terms: = Breast cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
305 results:
1. Lung Fibroblasts Take up breast cancer Cell-derived Extracellular Vesicles Partially Through MEK2-dependent Macropinocytosis.
Wan Y; Zhao Y; Cao M; Wang J; Tran SV; Song Z; Hsueh BW; Wang SE
Cancer Res Commun; 2024 Jan; 4(1):170-181. PubMed ID: 38259097
[TBL] [Abstract] [Full Text] [Related]
2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
3. Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer.
Li X; Liu C; Zhang X; Sun C; Ling J; Liu Y; Zuo Y; Cao Y; Zhang C; Jiang T; Wang M; Liu J; Lu J
Biomed Pharmacother; 2023 Dec; 168():115784. PubMed ID: 37879215
[TBL] [Abstract] [Full Text] [Related]
4. Inhibiting mek1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells.
Xue T; Fei S; Gu J; Li N; Zhang P; Liu X; Thompson PR; Zhang X
Philos Trans R Soc Lond B Biol Sci; 2023 Nov; 378(1890):20220246. PubMed ID: 37778380
[TBL] [Abstract] [Full Text] [Related]
5. Exosomes modified with anti-mek1 siRNA lead to an effective silencing of triple negative breast cancer cells.
Ferreira D; Santos-Pereira C; Costa M; Afonso J; Yang S; Hensel J; McAndrews KM; Longatto-Filho A; Fernandes R; Melo JB; Baltazar F; Moreira JN; Kalluri R; Rodrigues LR
Biomater Adv; 2023 Nov; 154():213643. PubMed ID: 37778291
[TBL] [Abstract] [Full Text] [Related]
6. Computational biology and in vitro studies for anticipating cancer-related molecular targets of sweet wormwood (Artemisia annua).
Dawood H; Celik I; Ibrahim RS
BMC Complement Med Ther; 2023 Sep; 23(1):312. PubMed ID: 37684586
[TBL] [Abstract] [Full Text] [Related]
7. Assessing the Antiproliferative Potential of a Novel Combretastatin A4 Derivative
Nazmy MH; Abu-Baih DH; Elrehany MA; Mustafa M; Aly OM; El-Sheikh AAK; Fathy M
Front Biosci (Landmark Ed); 2023 Aug; 28(8):185. PubMed ID: 37664933
[TBL] [Abstract] [Full Text] [Related]
8. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S
Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922
[TBL] [Abstract] [Full Text] [Related]
9. A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer.
Song R; Guo P; Ren X; Zhou L; Li P; Rahman NA; Wołczyński S; Li X; Zhang Y; Liu M; Liu J; Li X
Mol Cancer; 2023 Jul; 22(1):104. PubMed ID: 37408008
[TBL] [Abstract] [Full Text] [Related]
10. HDAC Inhibition Restores Response to HER2-Targeted Therapy in breast cancer via
Clayton NS; Carter EP; Fearon AE; Heward JA; Rodríguez Fernández L; Boughetane L; Wilkes EH; Cutillas PR; Grose RP
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047202
[TBL] [Abstract] [Full Text] [Related]
11. MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in breast cancer.
Tian Y; Chen ZH; Wu P; Zhang D; Ma Y; Liu XF; Wang X; Ding D; Cao XC; Yu Y
Adv Sci (Weinh); 2023 Apr; 10(12):e2204819. PubMed ID: 36815359
[TBL] [Abstract] [Full Text] [Related]
12. Long-Term Simulation of Microgravity Induces Changes in Gene Expression in breast cancer Cells.
Sahana J; Cortés-Sánchez JL; Sandt V; Melnik D; Corydon TJ; Schulz H; Cai Z; Evert K; Grimm D; Wehland M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674696
[TBL] [Abstract] [Full Text] [Related]
13. Upregulation of the EGFR/mek1/MAPK1/2 signaling axis as a mechanism of resistance to antiestrogen‑induced BimEL dependent apoptosis in ER
Hagan ML; Mander S; Joseph C; McGrath M; Barrett A; Lewis A; Hill WD; Browning D; McGee-Lawrence ME; Cai H; Liu K; Barrett JT; Gewirtz DA; Thangaraju M; Schoenlein PV
Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36524361
[TBL] [Abstract] [Full Text] [Related]
14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
Roskoski R
Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
[TBL] [Abstract] [Full Text] [Related]
15. A kinase inhibitor screen reveals mek1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.
Wester L; Venneker S; Hazenoot M; Pont C; Koedoot E; Timmermans AM; Martens JWM; Jansen MPHM; Kockx CEM; van IJcken WFJ; Meerman JHN; Zhang Y; van de Water B
Biochem Pharmacol; 2022 Oct; 204():115233. PubMed ID: 36041543
[TBL] [Abstract] [Full Text] [Related]
16. Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways.
Wang F; Yuan C; Liu B; Yang YF; Wu HZ
J Transl Med; 2022 Jul; 20(1):310. PubMed ID: 35794555
[TBL] [Abstract] [Full Text] [Related]
17. Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in breast cancer Cells.
Amante RJ; Auf der Maur P; Richina V; Sethi A; Iesmantavicius V; Bonenfant D; Aceto N; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2022 Jun; 27(2):145-153. PubMed ID: 35739379
[TBL] [Abstract] [Full Text] [Related]
18. Oncogenic Long Noncoding RNA Linc01287 Promotes IGF1R Expression by Sponging miR-98 in breast cancer.
Guo C; Zhang M; Qian J; Li P; Guo L
Crit Rev Eukaryot Gene Expr; 2022; 32(3):31-44. PubMed ID: 35695608
[TBL] [Abstract] [Full Text] [Related]
19. Altersolanol B, a fungal tetrahydroanthraquinone, inhibits the proliferation of estrogen receptor-expressing (ER+) human breast adenocarcinoma by modulating PI3K/AKT, p38/ERK MAPK and associated signaling pathways.
Siraj MA; Jacobs AT; Tan GT
Chem Biol Interact; 2022 May; 359():109916. PubMed ID: 35346647
[TBL] [Abstract] [Full Text] [Related]
20. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract] [Full Text] [Related]
[Next]
